Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
GBM: early-phase trial registry
12 of 25 indexed GBM trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #652 of 28,707 conditions by registered trial count.
25 US clinical trials · 12 currently recruiting · #652 of 28,707 conditions by registered trial count
GBM: 25 US clinical trials tracked, 12 recruiting.
GBM is the subject of 25 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most active sponsor is Northwell Health, running 6 of these trials.
Enrollment posture brief
Registry condition gbm
OPEN 12 | RECR 48% | LATE 3 | EARLY 18 | RANK #652 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Diabetes Type 2 (48% recruiting · 25 trials)
GBM lists 12 open slots (48% of 25 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for GBM on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
GBM is recruiting above its size-band peers.
12 of 25 indexed trials (48%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates GBM research.
Northwell Health accounts for 6 of 25 trials (24%). 19 distinct sponsors appear on at least one study for this condition label.
-
Most GBM trials plan to enrol fewer than 100 people.
Median target enrolment is 57 among the 25 trials that report a genuine target (sentinel values excluded). 17 of those (68%) plan for fewer than 100 participants.
-
GBM research is mostly interventional.
25 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
25 total, page 1 of 1
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
Ivy Brain Tumor Center
NCT06388733
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
Northwell Health
NCT05271240
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma
NCT05933265
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Black Diamond Therapeutics
NCT07326566
WBSI Guided Personalized Delivery of TTFields
Abramson Cancer Center at Penn Medicine
NCT05086497
Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma
Alpheus Medical
NCT07225621
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Orbus Therapeutics
NCT05879367
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
Northwell Health
NCT02861898
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
Northwell Health
NCT05954858
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Henry Ford Health System
NCT05686798
Sonodynamic Therapy in Patients With Recurrent GBM
Shayan Moosa, MD
NCT06039709
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
Northwell Health
NCT05979064
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
CarThera
NCT05902169
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Sapience Therapeutics
NCT04478279
Surgical Nivolumab And Ipilimumab For Recurrent GBM
Patrick Wen, MD
NCT04606316
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
Northwestern University
NCT04528680
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
Nader Sanai
NCT05076513
Niraparib/TTFields in GBM
Abramson Cancer Center at Penn Medicine
NCT04221503
Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma
Jethro Hu
NCT03451799
Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM
Northwell Health
NCT03630289
Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma
Diffusion Pharmaceuticals
NCT01465347
PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
Massachusetts General Hospital
NCT01112527
Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA
Northwell Health
NCT01238237
Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma
Icahn School of Medicine at Mount Sinai
NCT03341806
GW572016 to Treat Recurrent Malignant Brain Tumors
National Cancer Institute (NCI)
NCT00107003
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 5 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on GBM records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on GBM trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this GBM page
25 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 GBM trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Northwell Health sponsors the most GBM trials on record, review their full trial history before evaluating a specific study. See Northwell Health's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This GBM condition card totals 25 registered trials; most-linked intervention Temozolomide; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.